Deans' stroke musings: Nasal spray to treat anxiety moves forward with global phase 3 trial

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Saturday, May 14, 2022

Nasal spray to treat anxiety moves forward with global phase 3 trial

You'll have to demand your doctor treat the cause of your anxiety(lack of 100% recovery protocols) rather than the secondary problem of anxiety. If you know that doing these EXACT PROTOCOLS you will get 100% recovery, you won't have anxiety. SOLVE THE CORRECT PROBLEM!

Post stroke anxiety(20% chance).

Nasal spray to treat anxiety moves forward with global phase 3 trial

By Ken Downey Jr.

Source/Disclosures

ADD TOPIC TO EMAIL ALERTS

VistaGen Therapeutics and AffaMed Therapeutics announced a global phase 3 trial to assess the efficacy, safety and tolerability of a nasal spray that treats adults with social anxiety disorders.

Dubbed the PALISADE Global trial, the companies have submitted necessary data to the FDA under its existing PH94B investigational new drug application for the nasal spray. The trial is expected to begin in the United States and China in the second half of 2022.

PH94B is odorless, fast-acting neuroactive spray with a potential mechanism of action for the acute treatment of anxiety in adults.

“VistaGen remains committed to transforming the treatment of anxiety disorders for the millions of individuals worldwide who need better, safer, and faster-acting therapeutics in their journey toward mental health wellness,” VistaGen CEO Shawn Singh said in statement.

In June 2020, VistaGen entered into a licensing and collaboration agreement with AffaMed for the clinical development and commercialization of PH94B for those in China, South Korea and South Asia.

VR shows promise in reducing stress, anxiety among health care providers
Pandemic, racism linked to postpartum anxiety, depression in Black mothers

“We appreciate VistaGen’s essential work in the U.S. under its PH94B [investigational new drug] application with the FDA,” AffaMed CEO Dayao Zhao, PhD, said in the release. “We thank the [National Medical Products Association] for recognizing the importance of this phase 3 study and rapidly expediting the approval of our [clinical trial application]. We look forward to dosing participants later this year.”